ArticleJAMA network open2021

Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.

Samantha Wilkinson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.